Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
itraconazole + cisplatin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Ain Shams University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy, investigated by Ain Shams University, involves the addition of the oral antifungal agent itraconazole to standard platinum-based chemotherapy (typically cisplatin or carboplatin plus gemcitabine) for the treatment of advanced non-small cell lung cancer (NSCLC). Itraconazole is repurposed here for its potent anti-angiogenic properties, which include the inhibition of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) signaling, as well as the Hedgehog and AKT/mTOR pathways. By targeting multiple angiogenic and survival pathways, itraconazole aims to enhance the efficacy of cytotoxic chemotherapy. Clinical results from a Phase 2 trial (NCT03664115) demonstrated improved objective response rates and progression-free survival in metastatic NSCLC patients compared to chemotherapy alone.
- Other names
- itraconazole + platinum-based chemotherapyitraconazole + carboplatin + gemcitabine
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)SMO (Smoothened)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AMPK (Adenosine monophosphate–activated protein kinase)FGFR (FGFR family)mTOR (Mammalian target of rapamycin kinase)VEGFR (VEGFR family)
Beyond the preview
Go deeper on itraconazole + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on itraconazole + cisplatin + gemcitabine.